Cost is not the primary barrier keeping Americans from weight loss drugs, despite historically high list prices and inconsistent insurance coverage, according to a March 17 Axios-Ipsos poll.
The finding is based on survey responses from a nationally representative sample of 1,225 U.S. adults polled March 6-9.
Three takeaways:
1. Among those not interested in GLP-1s, just 16% cited cost as the main reason. The most commonly cited factor for not using the medications was preferring to manage weight through diet and exercise (51%), followed by concerns about side effects (38%).
2. Still, the data show GLP-1 use continues to increase. Eighteen percent of Americans reported that they or a family member or friend is using a weight loss drug, up from 12% a year ago. About 11% said they have personally used a GLP-1.
3. The finding comes amid heightened concerns over healthcare costs more broadly. Sixty-nine percent of respondents said they are worried about potential insurance cost increases in 2026, and 68% said a 10% rate hike would negatively impact their household finances.
See the full survey here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
